{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT02952508: Phase 2 Interventional Active, not recruiting Waldenstrom Macroglobulinemia
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
NM404 I-131 (also known as CLR 131) is a phospholipid ether analog labeled with iodine I-131, used as radiotherapeutic and positron emission tomography (PET) radioimaging agent. Upon infusion, the drug accumulates in tumor cells and is retained for a long time because of the decreased activity of a phospholipase D. The drug is being developed by Cellectar Biosciences and is investigated in clinical trials against multiple myeloma and hematologic malignancies. In 2014, the FDA granted orphan drug designation for CLR 131 for the treatment of multiple myeloma.
Status:
Investigational
Source:
NCT02462603: Phase 2 Interventional Completed Parkinson's Disease
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04542850: Not Applicable Interventional Completed SARS-CoV 2
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:esoxybutynin [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Esoxybutynin is (S)-enantiomer of oxybutynin. Esoxybutynin exerts antimuscarinic properties. Racemic oxybutynin is used clinically to treat urinary incontinence. Sepracor was developing (S)-oxybutynin, a single-isomer version of Alza's Ditropan (racemic oxybutynin), a muscarinic acetylcholine receptor antagonist, as a potential treatment for urinary incontinence.
Status:
Investigational
Source:
Clin Pharmacol Ther. May 2021;109(5):1274-1281.: Not Applicable Human clinical trial Completed Multiple System Atrophy/blood
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
Nutrients. Jun 2019;11(7):.: Not Applicable Human clinical trial Completed N/A
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02977689: Phase 2 Interventional Withdrawn Glioma
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04535193: Phase 1/Phase 2 Interventional Recruiting Cardiovascular Diseases
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT02956148: Early Phase 1 Interventional Completed Huntington's Disease
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT02978599: Phase 1 Interventional Completed Schizophrenia
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
AVL-3288 is a type I selective positive allosteric modulator of α7 nACHRs. It represents a "first-in-class" drug for the treatment of cognitive deficits in CNS disorders such as schizophrenia and potentially other diseases of cognitive impairment such as Alzheimer’s disease and ADHD. AVL-3288 was successfully tested in representative animal models of cognitive dysfunction in schizophrenia, a disease where α7 nAChR function is impaired. To date, no specific treatments for cognitive deficits in schizophrenia exist and approved therapies do not satisfactorily improve cognition.
AVL-3288 is currently in human phase I trials.
